Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo

Yang, Yajun; Xiu, Jinghui; Zhang, Lianfeng; Qin, Chuan; Liu, Jiangning

doi:10.1016/j.phymed.2012.08.012

Cited by 44 publications

(36 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Punicalagin exhibits multiple biological effects, including antioxidant, antiproliferative, antiviral, and antimicrobial activities (Taguri et al, 2004;Aqil et al, 2012;Yang et al, 2012;Xu et al, 2016). Moreover, it has shown anti-inflammatory properties both in vitro and in vivo (Jean-Gilles et al, 2013;Olajide et al, 2014;Xu et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Punicalagin protects bovine endometrial epithelial cells against lipopolysaccharide-induced inflammatory injury

Lyu

Chen

Wang

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: Bovine endometritis is one of the most common reproductive disorders in cattle. The aim of this study was to investigate the anti-inflammation potential of punicalagin in lipopolysaccharide (LPS)-induced bovine endometrial epithelial cells (bEECs) and to uncover the underlying mechanisms. Methods: bEECs were stimulated with different concentrations (1, 10, 30, 50, and 100 μg/ml) of LPS for 3, 6, 9, 12, and 18 h. MTT assay was used to assess cell viability and to identify the conditions for inflammatory injury and effective concentrations of punicalagin. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess gene expression of pro-inflammatory cytokines. Western blotting was used to assess levels of inflammation-related proteins. Results: Treatment of bEECs with 30 µg/ml LPS for 12 h induced cell injury and reduced cell viability. Punicalagin (5, 10, or 20 µg/ml) pretreatment significantly decreased LPS-induced productions of interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-α (TNF-α) in bEECs. Molecular research showed that punicalagin inhibited the activation of the upstream mediator nuclear factor-κB (NF-κB) by suppressing the production of inhibitor κBα (IκBα) and phosphorylation of p65. Results also indicated that punicalagin can suppress the phosphorylation of mitogen-activated protein kinases (MAPKs) including p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK). Conclusions: Punicalagin may attenuate LPS-induced inflammatory injury and provide a potential option for the treatment of dairy cows with Escherichia coli endometritis.

show abstract

Section: Introductionmentioning

confidence: 99%

Punicalagin protects bovine endometrial epithelial cells against lipopolysaccharide-induced inflammatory injury

Lyu

Chen

Wang

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…Punicalagin is a major antioxidant polyphenol in pomegranate juice, where it may reach levels of up to 1 g/L of juice [21]. It has potential antiviral effect against enterovirus 71 and could be used for the therapy of various immune pathologies [22].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of telomerase activity and cell growth by free and nanoliposomal forms of punicalagin in human leukemia cell line K562

Ghorbanihaghjo¹,

Faezizadeh²,

Godarzee³

2016

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To prepare punicalagin-loaded nanoliposome and compare its anti-telomerase activity in K562 cell line with that of free punicalagin. Methods: Punicalagin-loaded nanoliposomes were prepared by extrusion method, and the efficiency of punicalagin entrapment was determined by high-performance liquid chromatography (HPLC) method. The anti-proliferation effect of the punicalagin in the free and nanoliposomal forms at various doses (0 -100 µg/mL) and times (0 -72 h) on K562 cell line was investigated using 3-(4,5-dimethylthiazol-2-yl)-

show abstract

“…CHLA and PUG have also antiviral activities against HCMV, HCV, DENV, MV and RSV 205 . PUG treatment also protected mice challenged with an otherwise lethal dose of enterovirus 206 . While the exact mechanism of action of CHLA and PUG is not entirely elucidated, it is suggested that these compounds inhibit the interaction between viral glycoproteins and cellular glycosaminoglycans (GAGs) 207 .…”

Section: Bsas Derived From Plants: Castanospermine 1-deoxynojirimycimentioning

confidence: 95%

Antiviral drug discovery: broad-spectrum drugs from nature

et al. 2015

View full text Add to dashboard Cite

, but cannot be converted to PDF. You must view these files (e.g. movies) online.Scheme 1_(structures 1-5)_named.cdx Scheme 2_(structures 6-8)_named.cdx Scheme 3_(structure 9)_named.cdx Scheme 4_(structure 10)_named.cdx Scheme 5_ (structures 11-12) The development of drugs with broad-spectrum antiviral activities is a long pursued goal in drug discovery. It has been shown that blocking co-opted host-factors abrogates the replication of many viruses, yet the development of such host-targeting drugs has been met with skepticism mainly due to toxicity issues and poor translation to in vivo models. With the advent of new and more powerful screening assays and prediction tools, the idea of a drug that can efficiently treat a wide range of viral infections by blocking specific host functions has rebloomed. Here we critically review the state-of-the-art in broad-spectrum antiviral drug discovery. We discuss putative targets and treatment strategies, taking particular focus on natural products as promising starting points for antiviral lead development.

show abstract

Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo

Cited by 44 publications

References 21 publications

Punicalagin protects bovine endometrial epithelial cells against lipopolysaccharide-induced inflammatory injury

Punicalagin protects bovine endometrial epithelial cells against lipopolysaccharide-induced inflammatory injury

Inhibition of telomerase activity and cell growth by free and nanoliposomal forms of punicalagin in human leukemia cell line K562

Antiviral drug discovery: broad-spectrum drugs from nature

Contact Info

Product

Resources

About